Evonik presents mRNA formulation innovations at Korean Global Vaccine Business Forum
Evonik presents mRNA formulation innovations at Korean Global Vaccine Business Forum
Reconfirming Evonik’s global leadership role and its contribution to fight COVID-19
• Presenting competencies in custom lipids and lipid nanoparticles
• Evaluating future collaboration opportunities
Seoul, South Korea. Evonik highlighted its activities in the field of mRNA-based therapies and nanomedicines at a virtual business forum organized by the Ministry of Trade of South Korea on November 29th, 2021. Led by Mr Han-Koo Yeo, Trade Minister from the Ministry of Trade, Industry & Energy (MOTIE), the forum brought together the Korean trade organizations MOTIE and KOTRA, with 14 international and over 20 Korean companies. The WHO and the Coalition for Epidemic Preparedness (CEPI) also presented at the forum. South Korea – already a producer of four of the global mRNA vaccines – aims to establish a stronger foothold in the manufacturing and development of vaccines.
“Drug delivery is essential – as important as the mRNA – for the successful manufacture of mRNA vaccines. We were honored that the Ministry of Trade of South Korea recognizes the potential of mRNA technology and invited us to participate in this important forum,” says Paul Spencer, head of the product line Drug Delivery & Medical Device Solutions at Evonik’s Health Care business line.
As a fully integrated Contract Development Manufacturing Organization (CDMO) for mRNA delivery technologies, Evonik Health Care is a frontrunner in custom lipids, mRNA-LNP drug delivery systems, clinical and commercial cGMP aseptic manufacturing, and research and development activities.
Evonik already has two sites in South Korea: a research and development site in Bucheon, and a production site in Ulsan. The attractive innovative business setting of South Korea opens important opportunities for Evonik to cooperate with Korean companies on lipid CDMO and formulation services and with Korean universities and start-ups working on new technologies
and excipients. Evonik can also provide access to North American clinical and commercial parenteral manufacturing facilities for Korean partners.
Lipid-based parenteral drug delivery plays a pivotal role in the rapid development and application of novel mRNA therapeutics. Consequently, the Covid-19 pandemic has accelerated the portfolio of system solutions for advanced drug delivery at Evonik Health Care, which is part of the life sciences division Nutrition & Care.
Evonik Korea , President Mr. Tomas Choi
Mr. Choi Yoon-young (Tomas Choi), branch manager of Evonik Korea, serves as chairman of the chemical industry committee of the Global Enterprise CEO Association in Korea (G-CEO) under the jurisdiction of the Ministry of Trade, Industry and Energy.
송인선 기자aliciasong8@gmail.com